Vanguard Group Inc. Has $88.10 Million Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Vanguard Group Inc. increased its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 27.1% in the fourth quarter, HoldingsChannel reports. The firm owned 4,822,139 shares of the company’s stock after purchasing an additional 1,027,623 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Eyepoint Pharmaceuticals worth $88,100,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue acquired a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth about $76,000. Tower Research Capital LLC TRC grew its holdings in Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after acquiring an additional 5,967 shares during the last quarter. Finally, Bank of Nova Scotia bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth about $158,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Down 1.4%

Eyepoint Pharmaceuticals stock opened at $13.43 on Thursday. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $5.30 and a 1 year high of $19.11. The company has a market cap of $1.13 billion, a PE ratio of -3.84 and a beta of 1.76. The company’s 50-day moving average is $13.99 and its two-hundred day moving average is $14.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.3 EPS for the current year.

Insider Transactions at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 4.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on EYPT. Chardan Capital increased their price objective on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. HC Wainwright increased their price objective on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Citigroup increased their price objective on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, Royal Bank Of Canada decreased their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $31.80.

Eyepoint Pharmaceuticals Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.